Pemafibrate
Pemafibrate
Pemafibrate is a novel fibrate drug that acts as a selective peroxisome proliferator-activated receptor (PPAR) alpha modulator. It is primarily used for the treatment of dyslipidemia, particularly in reducing triglyceride levels and improving lipid profiles in patients with hyperlipidemia.
Mechanism of Action
Pemafibrate functions by selectively modulating the activity of the PPAR-alpha receptor, which plays a crucial role in the regulation of lipid metabolism. By activating PPAR-alpha, pemafibrate enhances the oxidation of fatty acids and increases the catabolism of triglyceride-rich particles, leading to a reduction in plasma triglyceride levels. This mechanism also contributes to an increase in high-density lipoprotein (HDL) cholesterol levels.
Clinical Use
Pemafibrate is indicated for the treatment of hyperlipidemia, particularly in patients who have not achieved adequate control of their lipid levels through diet and lifestyle modifications alone. It is often prescribed to patients with hypertriglyceridemia to reduce the risk of cardiovascular disease.
Pharmacokinetics
Pemafibrate is administered orally and is well absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is primarily excreted in the urine. The drug has a favorable pharmacokinetic profile, with a long half-life that allows for once-daily dosing.
Side Effects
Common side effects of pemafibrate include mild gastrointestinal disturbances, such as nausea and diarrhea. Some patients may experience muscle pain or myopathy, although these effects are less common compared to other fibrates. Regular monitoring of liver function tests is recommended during treatment.
Comparison with Other Fibrates
Compared to traditional fibrates like fenofibrate and gemfibrozil, pemafibrate offers a more selective action on PPAR-alpha, which may result in a better safety profile and fewer drug interactions. Its selectivity also contributes to its efficacy in lowering triglyceride levels and improving HDL cholesterol.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD